1. Scrip
  2. >>Business

Teva Advancing Two Advair Generics With Late 2017 Target

 
• By Jessica Merrill

Teva will move forward an internal generic Advair candidate and one acquired from Allergan to improve its chances of getting an interchangeable version of the market-leading asthma drug approved by FDA.

Pills

Teva Pharmaceutical Industries Ltd. is doubling down on its efforts to develop an interchangeable generic Advair. The company will advance an internal candidate and a second acquired with the acquisition of Allergan PLC’s generic drug business, Teva Global Generic Medicines Group President and CEO Sigurdur Olafsson said during the company’s second quarter sales and earnings call Aug. 4.

The financial update fell just days after the Federal Trade Commission cleared Teva’s $40.5bn acquisition of Allergan’s generic drug business...

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Scrip for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from Earnings

More from Business

Syncona Looks To Go Private As Market Decline Deepens

 
• By Andrew McConaghie

While some are calling for Syncona to be wound up, the UK-based company believes many existing and new investors will back the creation of new private fund.

ASCO: Pushing The Frontiers Of ADCs

 
• By Mary Jo Laffler

Antibody-drug conjugates are a major part of the oncology pipeline, and data presented at the American Society of Clinical Oncology meeting highlight the emergence of new technologies.

Top 10 Drugs Q1 2025: Keytruda Dominates; Mounjaro Climbs

 
• By Eleanor Malone

Lilly’s Mounjaro for diabetes rose from sixth to third position among the top-selling drugs in the first quarter of 2025, Rival Ozempic retained second position and Merck & Co’s immuno-oncology blockbuster Keytruda stayed far ahead.